The FDA has accepted the new drug application (NDA) for SH 201, the first palatable oral liquid of the related chemotherapeutic agent, for the treatment of certain forms of leukemia and other cancers
Recent research has demonstrated that telomere maintenance might be a key integrating point for the cumulative effect of genetic and environmental factors in patients with first-episode psychosis (FEP) and schizophrenia (SCZ).
Intra-Cellular Therapies, Inc. announced an independent data monitoring committee (DMC) has completed a pre-specified interim analysis of the Company�s ongoing...
Orion Corporation has entered into a global partnership with Bayer for the development and commercialization of the compound ODM-201, an...